44 results about "Bone morphogenetic protein 4" patented technology

A serum-free cryoprotectant includes: 8-15 v/v% of DMSO, 85-92 v/v% of a DMEM basic culture medium, and a nutritional additive. The nutritional additive includes: fibroblast growth factors, insulin, growth hormone, transferrin, bone morphogenetic protein 4, glutamine, sodium pyruvate, beta-mercaptoethanol, human epidermal growth factor, sodium selenite, and various amino acids and vitamins. The cryoprotectant is free of animal sourced serum and avoids pollution and risk of allergen, and has better clinical safety. The serum-free cryoprotectant is suitable for cryopreservation of human placenta sourced, umbilical cord sourced and cord blood sourced mesenchymal stem cells; compared with common serum cryoprotectants, perinatal mesenchymal stem cells preserved in the cryoprotectant have high cell survival rate after resuscitation, have excellent adherence growth status and maintain biological characters well.

The invention provides an adult regulatory T cell in-vitro amplification culture medium and an application method thereof. The adult regulatory T cell in-vitro amplification culture medium comprises transform growth factor-beta (1-4 ng/ml), bone morphogenesis protein 4 (8-12 ng/ml), recombinant human interleukin-2 (300-500U/ml), rapamycin (80-100nM/ml), al-trans vitamin A acid (1-4 uM/mL), 4-hydroxyethylpiperazinoethylsulfonic acid (20-30mM/ml), L-glutamine (2mM/ml), 2-mercaptoethanol (40-50uM/ml), 5% human AB type serum, CD3CD28 magnetic bead, penicillin (50U/ml) and streptomycin (50ug/ml). When being used for performing amplification culture and induced differentiation on regulatory T cells, the culture medium can shorten the amplification and differentiation time of the regulatory T cells, and can obtain the high-purity Foxp3CD4+CD25+CD127-regulatory T cells. Therefore, the regulatory T cells can be used in the aspect of clinical treatment of anti-transplantation immunity rejection, autoimmune disease, allergic disease and the like to perform a novel clinical cell therapy.

The invention relates to methods for preparing pleuripotent cardiovascular progenitor cells and maintaining cardiovascular differentiation capacity and discloses a method for inducing and differentiating pluripotent stem cells into the pleuripotent cardiovascular progenitor cells for the first time. The method comprises the step of carrying out induction by utilizing ascorbic acid, a bone morphogenetic protein 4 and a glycogen synthase kinase-3 inhibitor. The invention further provides a method for stably culturing the pleuripotent cardiovascular progenitor cells. The method comprises the steps of enabling the pleuripotent cardiovascular progenitor cells to stably grow and carry out generation transfer by utilizing a BMP (bone morphogenetic protein) signal channel inhibitor, an activin/Nodal signal channel inhibitor and a glycogen synthase kinase-3 signal channel inhibitor. The pleuripotent cardiovascular progenitor cells prepared by utilizing the method can be further differentiated into cells including myocardial cells, vascular smooth muscle cells or vascular endothelial cells in a cardiovascular pedigree and can be applied to the treatment and myocardial regeneration research of heart diseases, the pharmaceutical cardiovascular cytotoxicity detection and the development of heart medicaments.

The invention discloses a vascular endothelial cell culture method. The method comprises the following steps: 1) differentiating pluripotent stem cells into mesendoderm precursor cells in a culture medium A; 2) differentiating the mesendoderm precursor cells into progenitor cells of vascular endothelial cells in a culture medium B; 3) differentiating the progenitor cells of the vascular endothelial cells into the vascular endothelial cells in a culture medium C. The culture medium A contains a DMEM, an F12 culture medium, sodium selenate, sodium bicarbonate, vitamin C, insulin, an activin A , bone morphogenetic protein-4 and a glycogen synthase kinase-3 inhibitor; the culture medium B contains a DMEM, an F12 culture medium, sodium selenate, sodium bicarbonate, vitamin C, insulin, a vascular endothelial growth factor and a transforming growth factor beta signaling pathway inhibitor; the culture medium C contains a DMEM, an F12 culture medium, sodium selenate, sodium bicarbonate, vitamin C, insulin, a vascular endothelial growth factor, an epidermal growth factor and a fibroblast growth factor. According to the method, the pluripotent stem cells can be differentiated into the vascular endothelial cells.

The invention discloses an eccrine sweat gland cell induction medium and an application thereof. The eccrine sweat gland cell induction medium comprises a DMEM/F12 cell medium, a keratinocyt medium, fetal calf serum, an epidermal growth factor, triiodothyronine, hydrocortisone, insulin-transferrin-sodium selenite, L-glutamine, penicillin, streptomycin, a hepatocyte growth factor and a bone morphogenetic protein 4. The eccrine sweat gland cell induction medium disclosed by the invention can be used for successfully inducing stem cells to be directionally differentiated to eccrine sweat gland-like cells so as to provide sufficient eccrine sweat gland cells for treating extensive burn patients, so that the living quality of the patients is greatly improved. The medium further provides a theoretical basis for researching differentiated development of the sweat gland, so that the medium has a potential clinical application prospect.

The present invention relates to an application of bone morphogenetic protein 4 in cancer inhibition. Specifically bone morphogenetic protein (BMP) has a liver cancer stem cell differentiation induction effect, wherein CD133 protein expression of liver cancer cell lines can be down-regulated and liver cancer cell line CD133+ liver cancer stem cell differentiation can be promoted with BMP4, and BMP4 can further be provided for inhibiting in vitro proliferation and self-renewal of liver cancer cell lines and inhibiting tumorigenicity of immune-deficient mice. The present invention further provides BMP4-induced liver cancer stem cell differentiation action mechanism.

The invention provides a pharmaceutical composition containing sodium alginate for cartilage tissue repairing. As an active ingredient of the composition, bone morphogenetic protein-4 transfected fat is derived from stem cells, sodium alginate and calcium chloride; by virtue of the composition, gaps filled between cartilage rods as well as between the cartilage rods and peripheral cartilages and subchondral bones are completely filled by regenerated tissues and mechanical properties similar to that of normal cartilage are guaranteed; full fusion of mosaic bones and cartilages with peripheral cartilages and subchondral bones is achieved, and joint function improvement and level recovery in postoperative patients are significantly improved; in addition, the invention also provides a preparation method of the pharmaceutical composition.

The invention provides an inducing agent for inducing directional differentiation of an embryonic stem cell into keratinocytes. The inducing agent comprises bone morphogenetic protein 4, retinoic acid and ascorbic acid. Preferably, in the inducing agent, the bone morphogenetic protein 4, retinoic acid and ascorbic acid are in a content ratio of (1-50g):(0.1-5 mol):(50-600mol). The inducing agent for inducing directional differentiation of the embryonic stem cell into keratinocytes combines the bone morphogenetic protein 4, retinoic acid and ascorbic acid, can effectively improve the efficiency for induced directional differentiation of hESC into keratinocytes (as high as 77.93%, and far higher than other formula inducing agents), provides an approach for efficiently inducing differentiation of hESC into keratinocytes, and provides seed cells for constructing tissue engineered oral mucosas.

The invention discloses a pluripotent stem cells directional differentiation method. The method is characterized in that pluripotent stem cells are cultured under cell culture environment of non exogenous hematopoietic cytokines, non serum, non matrix cells and clear component, after embryoid is formed, a vascular endothelial growth factor and bone morphogenetic protein 4 are added, the embryoid is attached on the surface spread with collagen IV, mesoderm differentiation is induced, and hemopoietic progenitor cells and blood corpuscles are generated. The cell culture system with determined component enables directional differentiation on the pluripotent stem cells, has the advantages of low cost, simple operation, high repeatability and ordered differentiation process, can massively generate hemopoietic progenitor cells and blood corpuscles, and has important meaning for researching a blood growth process mechanism.

The invention discloses an application of bone morphogenetic protein-4 in screening drugs for resisting cardiac hypertrophy, heart failure or cardiac fibrosis and belongs to the field of biomedicine. Screened drug types comprise: bone morphogenetic protein-4 formation inhibitor, bone morphogenetic protein-4 antagonistic, bone morphogenetic protein-4 receptor antagonists and bone morphogenetic protein-4 downstream signal antagonistic. The invention also relates to an application of the drugs in preparation of medicines for resisting cardiac hypertrophy, heart failure and arrhythmia. Researches have found that bone morphogenetic protein-4 can induce myocardial hypertrophy, apoptosis and cardiac fibroblast collagen secretion increase, lead to occurrence of cardiac hypertrophy, heart failure and arrhythmia. However, drugs for antagonism of bone morphogenetic protein-4 and its cell signaling pathway can be used to inhibit occurrence of cardiac hypertrophy, inhibit cardiac fibrosis and minimize occurrence of cardiac cell death and arrhythmia. The invention provides a theoretical basis for realizing high-flux medicine screening, and is of practical guiding significance.

The invention discloses a method for efficiently obtaining beating functional cardiomyocytes from mesenchymal stem cells. The method comprises the following steps: reprogramming the mesenchymal stem cells into pluripotent stem cells through mRNA reprogramming, and then adding an activin A and a bone morphogenetic protein 4 by adopting a matrix sandwich method to obtain the beating functional cardiomyocytes with differentiation efficiency of more than 80%. The differentiation efficiency of cardiomyocytes can be greatly improved by the method provided by the invention. The in vitro multiplication capacity of the cardiomyocytes is limited in the prior art, so the requirement for establishing the myocardium of tissue engineering in vitro cannot be met. The method provided by the invention can provide important experimental data for the research of cell therapy of ischemic cardiovascular diseases, and has a good clinical application prospect.

The invention relates to a culture medium for sweat gland cells and a preparation method of the culture medium. The culture medium comprises a basic culture solution and an additive, wherein the basic culture solution is an SGDM culture solution; the additive comprises the following components, by the addition amount in the basic culture solution, nerve growth factors, transforming growth factors-beta, epidermal growth factors, HEPG (heparin sulfate proteoglycan) and bone morphogenetic protein 4. The culture medium can increase the probability at which ips cells are induced into sweat gland cells, stable passage can be guaranteed, the cell proliferation speed is increased, and a source of seed cells is provided for skin tissue engineering. Additionally, no serum is used in the whole process, risks caused by animal origin pathogens are effectively avoided, and the clinical application safety is improved.

Disclosed is a novel method for formation of a tooth by producing a chimera embryoid body using an undifferentiated cell and a dental mesenchymal cell derived from a mammal of the same species as that of the target mammal and then cultivating the chimera embryoid body on a three-dimensional matrix. A tooth is formed by co-cultivating an undifferentiated cell and a dental mesenchymal cell derived from a mammal of the same species as that of the target mammal in the presence of an induction factor to produce a chimera embryoid body, and then cultivating the chimera embryoid body on a three-dimensional matrix. The cultivation of the chimera embryoid body on the three-dimensional matrix is performed either by cultivating the chimera embryoid body in a serum culture medium without the induction factor for three days; or cultivating the chimera embryoid body in a culture medium supplemented with the induction factor for two days, and further cultivating the chimera embryoid body in a serum culture medium without the induction factor for three days. The undifferentiated cell is at least one cell selected from all stem cells including an ES cell. The mammal is one selected from all mammals. The induction factor is activin, bone morphogenic protein 4, insulin growth factor 1, fibroblast growth factor 2, or transforming growth factor β1.

The present disclosure describes methods to promote thymic regeneration following injury or damage to the thymus by administering to the thymus an effective amount of (1) bone morphogenetic protein 4 (BMP4), (2) thymus-derived endothelial cells that express BMP4 or (3) a combination of BMP4 and BMP4-secreting thymus-derived endothelial cells.

The invention provides application of an extract composition of natural variform arsenite. The extract composition comprises extract of natural variform arsenite and at least one of the following anti-tumor medicines: camptothecin, vincaleukoblastinum, vincristine, taxol, tumor necrosis factor, interleukin, interferon, transforming growth factor-beta, lipopolysaccharide, phorbol ester, adenylate cyclase activating agent andbone morphogenetic protein 4, wherein the weight of the extract of the natural variform arsenite accounts for 0.001-99.9 percent of the total weight of the prepared medicine. The extract composition of natural variform arsenite can be used for preparing anti-tumor stem cells, anti-hepatitis B and anti-AIDS (acquired immune deficiency syndrome) virus medicines, can be used for inhibiting hepatitis B and resisting AIDS and other viruses, and expands the application range to development and utilization of natural arsenite preparations.

Arrays of nucleic acid molecules, kits, methods of genotyping and marker assisted bovine breeding methods based on novel SNPs on genes of the bovine transforming growth factor-β (TGF-β) signaling pathway for improved bovine fertilization rate. The methods and compositions of the present invention are related to SNPs in the DNA-binding protein inhibitor 3 (ID3) gene, and in the bone morphogenetic protein 4 (BMP4) gene corresponding to position 2702 of SEQ ID NO: 2. Also disclosed are methods for determining viability of developing bovine embryos by measuring the expression level of one or more target genes in the TGF-signaling pathway, and selecting for implantation only embryos whose target gene expression level is not up-regulated.

The invention discloses an induction medium for differentiating stem cells into sweat gland-like cells, and belongs to the technical field of stem cells. A induction culture medium is a DMEM/F-12 cell culture medium containing fetal bovine serum, an epidermal growth factor, a basic fibroblast growth factor, a recombinant human ectoderm dysplasia A1 protein, a recombinant human Wnt3a protein, a bone morphogenetic protein 4, a hepatocyte growth factor, triiodothyronine and hemisuccinyl hydrocortisone. The composition is prepared from insulin- transferrin-sodium selenite, L-glutamine and penicillin/streptomycin double antibiotics. The sweat gland induction culture medium can effectively induce stem cells, especially mesenchymal stem cells, to be differentiated into sweat gland-like cells with sweat gland-like cell phenotypes in vitro, the sweat gland-like cells can form a tubular structure similar to a sweat gland structure in glue, and the requirement for sweat glands in the treatment process of large-area burn patients can be met.

The invention relates to the field of molecular biology, and discloses an anti-foot-and-mouth disease drug and an application of ID1 protein and BMP4 (bone morphogenetic protein 4) protein in preparation of the same. An embodiment of the invention initially discover the relation of ID1 protein and the replication of the foot-and-mouth disease, which includes that the cure of the foot-and-mouth disease is realized through upregulating the expression of Id1. According to the function of the ID1 protein, the ID1 protein can be utilized in the preparation of the anti foot-and-mouth disease drug, and an important theoretical basis is provided in the development of new anti foot-and-mouth disease drug.